Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation.
Anti-thymocyte globulin
allogenic stem cell transplant
bone marrow transplant
graft versus host disease
in vivo t-cell depletion
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
14
4
2020
medline:
28
4
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
Anti-thymocyte globulin (ATG) has been associated with decreased rates graft versus host disease (GVHD) but with a potential risk of increasing risk of infection and relapse. We retrospectively studied the impact of single dose low dose (2.5 mg/kg) ATG in patients undergoing allogenic hematopoietic cell transplantation (HCT) from 8/8 matched unrelated donors (MUD). Of the total 209 patients identified, 129 received ATG. At baseline, the ATG group had more intermediate and high disease risk index (DRI) (64.6% vs. 54.3%) (28.3% vs. 23.7%)
Identifiants
pubmed: 32281491
doi: 10.1080/10428194.2020.1747067
doi:
Substances chimiques
Antilymphocyte Serum
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM